MGX vs. MRNA, TNXP, LXEO, JBIO, PBYI, ALLO, VOR, FENC, HUMA, and SGMT
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Tonix Pharmaceuticals (TNXP), Lexeo Therapeutics (LXEO), Jade Biosciences (JBIO), Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Vor Biopharma (VOR), Adherex Technologies (FENC), Humacyte (HUMA), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.
Metagenomi vs. Its Competitors
Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.
Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.
Metagenomi has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
75.3% of Moderna shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Moderna had 18 more articles in the media than Metagenomi. MarketBeat recorded 20 mentions for Moderna and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.76 beat Moderna's score of 0.85 indicating that Metagenomi is being referred to more favorably in the media.
Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.
Metagenomi presently has a consensus price target of $10.00, suggesting a potential upside of 443.48%. Moderna has a consensus price target of $42.88, suggesting a potential upside of 76.40%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Metagenomi is more favorable than Moderna.
Summary
Moderna beats Metagenomi on 9 of the 16 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
This page (NASDAQ:MGX) was last updated on 9/10/2025 by MarketBeat.com Staff
